Combination of plasma Tumor M2-PK and serum S100-beta
determinations improves estimation of prognosis in melanoma.
| marker combination | probability of overall survival 14 month after blood withdrawal |
| S100-β ≤ 0.12 μg/ml Tumor M2-PK ≤ 15 U/ml |
0.98 ( n = 204) |
| S100-β ≤ 0.12 μg/ml Tumor M2-PK > 15 U/ml |
0.95 ( n = 36) |
| S100-β > 0.12 μg/ml Tumor M2-PK ≤ 15 U/ml |
0.58 ( n = 39) |
| S100-β > 0.12 μg/ml Tumor M2-PK > 15 U/ml |
0.27 ( n = 21) |
Tumor M2-PK concentrations were measured in EDTA plasma with a sandwich ELISA from ScheBo Biotech AG Giessen, Germany.
S100-beta concentrations were measured in serum with a sandwich immunoluminometric assay (LIA-mat Sangtec 100) from Sangtec Medical, Bromma, Sweden).
Tumor M2-PK and S100-beta measurements: Selma Ugurel